Back to Journals » Vascular Health and Risk Management » Volume 6

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Authors Vergara-Jimenez J, Tricoci P

Published 2 March 2010 Volume 2010:6 Pages 39—45

DOI https://doi.org/10.2147/VHRM.S4168

Review by Single-blind

Peer reviewer comments 2


Jennifer Vergara-Jimenez, Pierluigi Tricoci

Department of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USA

Abstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and elective PCI. This large amount of information provides a clear efficacy and safety profile of the drug, although a few questions on the use of abciximab still exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic medications. In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI.
Keywords: abciximab, percutaneous coronary intervention, glycoprotein inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]